CARSON CITY, NV,, Sept. 10, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - Pharmagreen Biotech, Inc. (OTC PINKS: PHBI), is pleased to announce that its Canadian subsidiary, WFS Pharmagreen Inc., on September 5th formally submitted its proposal to the Fraser Valley Regional District Electoral Area Services Committee for the construction of the 62,000 square foot Cannabis Biotech Complex, situated on a 26 acre parcel of land in Deroche, B.C., Canada. This complex is designed for the production of cannabis tissue cultured starter plantlets. The proposed development was unanimously approved by this committee. The proposal now goes to the Fraser Valley Regional District Planning Board later this month for ratification of the Services Committee recommendation to allow the project to move forward to permitting stage.
Pharmagreen’s application to Health Canada submitted in June of 2018 for its Access to Cannabis for Medical Purposes Regulations (ACMPR) license is currently at the review stage.
Commenting on Pharmagreen’s progress, Peter Wojcik, President and CEO, stated, “We are very pleased with Pharmagreen’s progress and the recent approval by the regional municipal committee to move the project forward.”
About Pharmagreen Biotech, Inc. and WFS Pharmagreen Inc.
WFS Pharmagreen Inc. is a wholly owned Canadian based subsidiary of Pharmagreen Biotech, Inc., a publicly traded (OTC PINKS: PHBI) company. WFS Pharmagreen Inc. is a cannabis company that is becoming the largest producer of cannabis plantlets through a proprietary tissue culture process with opportunity to become one of the largest players globally. Pharmagreen’s mission is to advance the technology of tissue culture science and to provide the highest quality 100% germ free, disease free and all genetically the same plantlets of cannabis and other flora while offering full spectrum DNA testing for plant identification, live genetics preservation using low temperature storage for various cannabis and horticulture plants; extraction of botanical oils mainly CBD oil, and to deliver laboratory based services to the North American Cannabis and agriculture sectors. For further information on the company progress on the construction of a 62,000 square foot “Cannabis Biotech Complex” please visit www.pharmagreen.ca
Safe Harbor Statement
This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. In particular, factors that could cause actual results to differ materially from those in forward looking statements include: our inability to obtain additional financing on acceptable terms; risk that our products and services will not gain widespread market acceptance; inability to compete with others who provide comparable products; the failure of our technology; the infringement of our technology with proprietary rights of third parties; inability to respond to consumer demands; inability to replace significant customers; seasonal nature of our business. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements. When used in this document, the words "believe," "expect," "anticipate," "estimate," "project," "plan," "should," "intend," "may," "will," "would," "potential," and similar expressions may be used to identify forward-looking statements.
The OTC Markets or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release that has been prepared by management.